No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ARVN Arvinas
- 28.200
- -0.320-1.12%
Trading Jul 22 10:14 ET
1.93BMarket Cap-4661P/E (TTM)
28.840High28.110Low39.97KVolume28.580Open28.520Pre Close1.14MTurnover0.07%Turnover RatioLossP/E (Static)68.43MShares53.08052wk High3.16P/B1.60BFloat Cap13.57052wk Low--Dividend TTM56.90MShs Float108.465Historical High--Div YieldTTM2.56%Amplitude10.190Historical Low28.514Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | HOOKIPA Pharma : Sean Cassidy Appointed to Board of Directors
Express News | HOOKIPA Pharma Inc - Terry Coelho Appointed Evp and CFO at HOOKIPA
Express News | HOOKIPA Pharma Inc - DR. Malte Peters Named CEO at HOOKIPA
Express News | HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on Hb-200
Arvinas Repeat Insider Selling Not A Positive Indicator
Quite a few Arvinas, Inc. (NASDAQ:ARVN) insiders sold their shares over the past year, which may be a cause for concern. Knowing whether insiders are buying is usually more helpful when evaluating
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?
Comments
Arvinas' high P/S ratio could be worrisome as revenue forecasts are not promising. The anticipated future revenues may not sustain the current positive sentiment. Without significant improvements, these prices may not be deemed reasonable.
Revenues Not Telling The Story For Arvinas, Inc. (NASDAQ:ARVN) After Shares Rise 28% 1
Sean Cassidy expressed confidence in the company's future and the promising clinical development and commercial opportunity for the PROTAC(R) protein degrader pipeline. The company's leadership acknowledged Cassidy's pivotal role in creating Arvinas' strong financial profile.
1
$Arvinas(ARVN.US$ 👀 new hoy
$Arvinas(ARVN.US$ I hope everyone bought that sub 14 dip! This thing has been a beast.
1
Upgrades
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
16
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg